New blood gas device put to the test – but trial halted early
NCT ID NCT02801162
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compared a new device, the Proxima 3®, to standard hospital equipment for measuring blood gases like oxygen and carbon dioxide. Researchers wanted to see if the new device was accurate and fast in patients whose condition was changing quickly. The trial was stopped early after enrolling only 20 adults with arterial lines, so the findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Proxima 3® arterial blood gas analysis system
- What this could lead to
- If successful, this could provide a faster, reliable way to measure blood gases in rapidly changing clinical situations.
- What could go wrong
- The trial was terminated early with only 20 participants, so results are limited and may not be conclusive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universitair Ziekenhuis Brussel
Jette, Vlaams-Brabant, 1090, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common period drug double as an anaemia fix?
- Can remote care tame COPD Flare-Ups?
- Can a new MRI scan reveal hidden tumor weaknesses?
- Can a pill replace EPO shots for anemia in kidney disease?
- AI crystal ball for hospital wards: can software forecast oxygen drops 24 hours early?
- Thin air, thicker blood? hypoxia training may supercharge red blood cell production — at a cost